+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Contraceptive Drugs Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5786927

The global contraceptive drugs market size attained a value of USD 17.42 billion in 2022. The market is further expected to grow at a CAGR of 7.02% during the forecast period of 2023-2031 to attain a value of USD 32.08 billion by 2031. The growth of the market is driven by the increasing awareness and acceptance of contraceptive drugs.

Contraceptive Drugs Market: Introduction

Contraceptive drugs are medications that are used to prevent unwanted pregnancies by suppressing ovulation, altering the cervical mucus to prevent sperm from reaching the egg, or changing the lining of the uterus to prevent implantation. These drugs are available in different forms such as pills, patches, injections, vaginal rings, and implants.

There are two main types of contraceptive drugs: hormonal and non-hormonal. Hormonal contraceptive drugs contain synthetic versions of the female hormones oestrogen and progestin, or progestin alone, which work by inhibiting ovulation. Non-hormonal contraceptive drugs, on the other hand, work by altering the acidity of the cervical mucus or by creating a physical barrier that prevents sperm from reaching the egg.

Contraceptive drugs are widely used by women around the world to prevent unwanted pregnancies and to space out births. They are a safe and effective method of birth control when used correctly, but like any medication, they can have side effects. It is important to talk to a healthcare provider to determine the best contraceptive option based on an individual's medical history, lifestyle, and preferences.

Contraceptive Drugs Market Segmentations

Market Breakup by Product Type

  • Contraceptive Drugs
  • Contraceptive Pills
  • Patch
  • Injectables

Market Breakup by Route of Administration

  • Oral
  • Parentals
  • Topicals
  • Others

Market Breakup by Therapy Type

  • Monotherapy
  • Combined Contraceptives

Market Breakup by Age Group

  • 15-45 Years
  • Above 45 Years

Market by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Clinics
  • Online Channel
  • Public Channel
  • NGOs, Others

Contraceptive Drugs Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Contraceptive Drugs Market Scenario

The global contraceptive drugs market is expected to experience steady growth in the coming years. This market is driven by the increasing awareness and acceptance of contraceptive drugs as a means of birth control, especially among women.

The market is expected to be driven by various factors such as an increase in the prevalence of unwanted pregnancies and sexually transmitted diseases (STDs), a rise in the number of women in the workforce, and an increase in the availability of contraceptive drugs. Additionally, technological advancements, such as the development of new drugs with fewer side effects, are expected to drive market growth.

Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The Asia Pacific region is expected to experience the highest growth in the market due to the high population growth rate and increasing awareness of contraceptive drugs among women.

Overall, the global contraceptive drugs market is expected to experience steady growth in the coming years, driven by increasing awareness, technological advancements, and the introduction of new and improved drugs.

Key Players in the Global Contraceptive Drugs Market

The report gives an in-depth analysis of the key players involved in the contraceptive drugs market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

  • Piramal Enterprises Ltd
  • Agile Therapeutics
  • Johnson & Johnson Services, Inc
  • Abbive Inc
  • Merck & Co Inc
  • Teva Pharmaceuticals Industries Ltd
  • Bayer AG
  • Pfizer Inc
  • Helm AG
  • Reckitt Benckiser Group PLC
  • Viatris Inc
  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Allergan plc
  • Agile Therapeutics

This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Contraceptive Drugs Market Overview
3.1 Global Contraceptive Drugs Market Historical Value (2016-2022)
3.2 Global Contraceptive Drugs Market Forecast Value (2023-2031)
4 Global Contraceptive Drugs Market Landscape
4.1 Global Contraceptive Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Contraceptive Drugs Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Route of Administration
4.2.3 Analysis by Age Group
4.2.4 Analysis by Therapy Type
4.2.5 Analysis by Distribution Channel
5 Global Contraceptive Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Contraceptive Drugs Market Segmentation
6.1 Global Contraceptive Drugs Market by Product Type
6.1.1 Market Overview
6.1.2 Contraceptive Drugs Contraceptive Pills Patch Injectables
6.2 Global Contraceptive Drugs Market by Route of Administration
6.2.1 Market Overview
6.2.2 Oral
6.2.3 Parentals
6.2.4 Topicals
6.2.5 Others
6.3 Global Contraceptive Drugs Market by Therapy Type
6.3.1 Market Overview
6.3.2 Monotherapy
6.3.3 Combined Contraceptives
6.4 Global Contraceptive Drugs Market by Age Group
6.4.1 Market Overview
6.4.2 15-45 Years
6.4.3 Above 45 Years
6.5 Global Contraceptive Drugs Market by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacy
6.5.3 Retail Pharmacy
6.5.4 Clinics
6.5.5 Online Channel
6.5.6 Public Channel
6.5.7 NGOs, Others
6.6 Global Contraceptive Drugs Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Contraceptive Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Contraceptive Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Contraceptive Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.6 Australia
9.7 Others
10 Latin America Contraceptive Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Contraceptive Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Supplier Landscape
17.1 Piramal Enterprises Ltd.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Agile Therapeutics
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Johnson & Johnson Services, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Abbive Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Merck & Co Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Teva Pharmaceuticals Industries Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Bayer AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Helm AG.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Reckitt Benckiser Group PLC
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Viatris Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Amneal Pharmaceuticals LLC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Bayer AG
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Allergan plc.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 Agile Therapeutics
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
18 Global Contraceptive Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Piramal Enterprises Ltd.
  • Agile Therapeutics
  • Johnson & Johnson Services, Inc.
  • Abbive Inc.
  • Merck & Co Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Pfizer Inc.
  • Helm Ag.
  • Reckitt Benckiser Group plc
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC
  • Bayer AG
  • Allergan plc.
  • Agile Therapeutics



Table Information